The Library
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Tools
Tools
Tools
(2014) A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU International, 113 (5b). E137-E143. doi:10.1111/bju.12564 Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1111/bju.12564
Abstract
Objective:
To study the impact of the prognostic factors liver metastasis (LM), anaemia (haemoglobin [Hb] <10 g/dL), Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥1 and time from previous chemotherapy (TFPC) on the activity of second-line therapy for advanced urothelial carcinoma (UC).
Patients and methods:
Twelve phase II trials evaluating second-line chemotherapy and/or biological characteristics (n = 748) in patients with progressive disease were pooled. Progression-free survival (PFS) was defined as tumour progression or death from any cause. The PFS rate at 6 months (PFS6) was defined from the date of registration and calculated using the Kaplan-Meier method. Response rate (RR) was defined using Response Evaluation Criteria in Solid Tumours (RECIST) 1.0. A nomogram predicting PFS6 was constructed using the rms software package in R (http://www.r-project.org).
Results:
Data regarding progression, anaemia, LM, ECOG-PS and TFPC were available from 570 patients in nine phase II trials. The overall median PFS was 2.7 months, PFS6 was 22.2% (95% confidence interval 18.8-25.9) and the RR was 17.5% (95% CI: 14.5-20.9%). For every unit increase in risk group, the hazard of progression in 6 months increased by 41% and the odds of response decreased by 48%. A nomogram was constructed to predict PFS6 on an individual patient level. The model was internally validated and was shown to have acceptable calibration performance.
Conclusions:
The RR and PFS6 vary as a function of baseline prognostic factors in patients receiving second-line therapy for advanced UC. A nomogram incorporating prognostic factors facilitates the evaluation of outcomes across phase II trials enrolling heterogeneous populations and helps select suitable agents for phase III testing.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine | ||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Cancer Research Unit Faculty of Medicine > Warwick Medical School |
||||||||
| Library of Congress Subject Headings (LCSH): | Urinary organs -- Cancer, Nomography (Mathematics) | ||||||||
| Journal or Publication Title: | BJU International | ||||||||
| Publisher: | Wiley-Blackwell Publishing Ltd. | ||||||||
| ISSN: | 1464-1603 | ||||||||
| Official Date: | May 2014 | ||||||||
| Dates: |
|
||||||||
| Volume: | 113 | ||||||||
| Number: | 5b | ||||||||
| Number of Pages: | 7 | ||||||||
| Page Range: | E137-E143 | ||||||||
| DOI: | 10.1111/bju.12564 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Restricted or Subscription Access | ||||||||
| Funder: | Boehringer Ingelheim Pharmaceuticals, Celgene (Firm), Pierre Fabre Laboratories, AstraZeneca (Firm), British Mycological Society (BMS), GlaxoSmithKline |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
